Sinopharm Vaccine, SARS-CoV-2 breakthrough infections and Hemoglobinopathies

Abstract

To the editor.We read and followed the publication on the "Efficacy and Safety of Sinopharm Vaccine for SARS-CoV-2 and breakthrough infections in Iranian Patients with Hemoglobinopathies: A Preliminary Report". 1 According to Karimi et al., there were no safety concerns in patients who received two doses of the Sinopharm Vaccine. While its efficacy was not optimal due to the lack of effect on new virus variations, the data show that it appears protective against the severity of COVID-19 infection in patients with hemoglobinopathies. 1 We all agree that the inactivated COVID-19 vaccination protects against serious illness. The current report can confirm the safety and efficacy of certain vaccines with underlying hemoglobinopathies.

Adverse Effects of COVID-19 Vaccination in Patients with Transfusion-Dependent Thalassemia: An Observational Study from a Tertiary Care Center in Punjab, India

“…The safety and efficacy of the Sinopharm vaccine were also demonstrated in patients with HbE disease by a surrogate viral neutralization test. Headache and pain at the injection site were documented in almost 1/5th of the participants [17]. A 20-year-old patient with thalassemia and G6PD deficiency experienced acute hemolysis after receiving the ChAdOx1-S/nCoV-19 vaccine, as reported by Kongkiatkamon et al [21] Oxidative stress to red blood cells deficient in G6PD due to the COVID-19 vaccine was considered the cause of hemolysis in this patient.…”

“…The safety and efficacy of the Sinopharm vaccine were also demonstrated in patients with HbE disease by a surrogate viral neutralization test. Headache and pain at the injection site were documented in almost 1/5th of the participants [17].…”